ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

December 27, 2013

In Brief: NCAB Still Without New Appinees As Carter, Califano Delay Drags On; Keele to U. Kansas

January 19, 1979

In Brief: NCAB To Protest Tobacco Ads In ‘Family Circle’; ACS Petitions For Taxol Source Designation

October 19, 1990

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

NIH News: Board of Governors Appointed to Oversee Clinical Center

October 24, 1996

DCT Board Okays Concepts For New Radiation Studies

June 12, 1987